| The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects W Tang, Z Chen, W Zhang, Y Cheng, B Zhang, F Wu, Q Wang, S Wang, ... Signal transduction and targeted therapy 5 (1), 87, 2020 | 508 | 2020 |
| Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma GK Abou-Alfa, G Lau, M Kudo, SL Chan, RK Kelley, J Furuse, ... NEJM evidence 1 (8), EVIDoa2100070, 2022 | 504 | 2022 |
| The role of the novel Th17 cytokine IL-26 in intestinal inflammation J Dambacher, F Beigel, K Zitzmann, EN De Toni, B Göke, HM Diepolder, ... Gut 58 (9), 1207-1217, 2009 | 302 | 2009 |
| Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma … GK Abou-Alfa, SL Chan, M Kudo, G Lau, RK Kelley, J Furuse, ... Journal of Clinical Oncology 40 (4_suppl), 379-379, 2022 | 292 | 2022 |
| Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma J Ricke, HJ Klümpen, H Amthauer, I Bargellini, P Bartenstein, EN de Toni, ... Journal of hepatology 71 (6), 1164-1174, 2019 | 278 | 2019 |
| The novel mTOR inhibitor RAD001 (everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells K Zitzmann, EN De Toni, S Brand, B Göke, J Meinecke, G Spöttl, ... Neuroendocrinology 85 (1), 54-60, 2007 | 206 | 2007 |
| Checkpoint Inhibitors: the diagnosis and treatment of side effects L Heinzerling, EN de Toni, G Schett, G Hundorfean, L Zimmer Deutsches Ärzteblatt International 116 (8), 119, 2019 | 138 | 2019 |
| EFEMP1 Expression Promotes In vivo Tumor Growth in Human Pancreatic Adenocarcinoma H Seeliger, P Camaj, I Ischenko, A Kleespies, EN De Toni, SE Thieme, ... Molecular Cancer Research 7 (2), 189-198, 2009 | 124 | 2009 |
| Inhibition of ataxia telangiectasia-and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133+ … E Gallmeier, PC Hermann, MT Mueller, JG Machado, A Ziesch, ... Stem Cells 29 (3), 418-429, 2011 | 106 | 2011 |
| Inhibition of c-Jun-N-terminal-Kinase Sensitizes Tumor Cells to CD95-Induced Apoptosis and Induces G2/M Cell Cycle Arrest C Kuntzen, N Sonuc, EN De Toni, C Opelz, SR Mucha, AL Gerbes, ... Cancer research 65 (15), 6780-6788, 2005 | 103 | 2005 |
| Use of checkpoint inhibitors in liver transplant recipients S Munker, EN De Toni United European gastroenterology journal 6 (7), 970-973, 2018 | 100 | 2018 |
| OPG is regulated by â-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer EN De Toni, SE Thieme, A Herbst, A Behrens, P Stieber, A Jung, H Blum, ... Clinical cancer research 14 (15), 4713-4718, 2008 | 99 | 2008 |
| EFEMP1 binds the EGF receptor and activates MAPK and Akt pathways in pancreatic carcinoma cells P Camaj, H Seeliger, I Ischenko, S Krebs, H Blum, EN De Toni, ... Walter de Gruyter 390 (12), 1293-1302, 2009 | 96 | 2009 |
| Age independent survival benefit for patients with hepatocellular carcinoma (HCC) without metastases at diagnosis: a population-based study EN De Toni, A Schlesinger-Raab, M Fuchs, W Schepp, U Ehmer, ... Gut 69 (1), 168-176, 2020 | 89 | 2020 |
| Inhibition of Src tyrosine kinase reverts chemoresistance toward 5-fluorouracil in human pancreatic carcinoma cells: an involvement of epidermal growth factor receptor signaling I Ischenko, P Camaj, H Seeliger, A Kleespies, M Guba, EN De Toni, ... Oncogene 27 (57), 7212-7222, 2008 | 87 | 2008 |
| Mood, cognition and EEG changes during interferon á (alpha-IFN) treatment for chronic hepatitis C P Amodio, EN De Toni, L Cavalletto, D Mapelli, E Bernardinello, ... Journal of affective disorders 84 (1), 93-98, 2005 | 85 | 2005 |
| Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient EN De Toni, AL Gerbes Gastroenterology 152 (6), 1631-1633, 2017 | 82 | 2017 |
| JNK inhibition sensitises hepatocellular carcinoma cells but not normal hepatocytes to the TNF-related apoptosis-inducing ligand SR Mucha, A Rizzani, AL Gerbes, P Camaj, WE Thasler, CJ Bruns, ... Gut 58 (5), 688-698, 2009 | 81 | 2009 |
| Targeting cyclin dependent kinase 5 in hepatocellular carcinoma–A novel therapeutic approach SM Ehrlich, J Liebl, MA Ardelt, T Lehr, EN De Toni, D Mayr, L Brandl, ... Journal of hepatology 63 (1), 102-113, 2015 | 80 | 2015 |
| Tumor and circulating biomarkers in patients with second-line hepatocellular carcinoma from the randomized phase II study with tivantinib L Rimassa, G Abbadessa, N Personeni, C Porta, I Borbath, B Daniele, ... Oncotarget 7 (45), 72622, 2016 | 72 | 2016 |
Burkhard GokeConsulting ProfessorVerified email at uke.de
